Chemoembolization Contraindications in Liver Disease

Primary Contraindication in Decompensated Cirrhosis

Chemoembolization is explicitly discouraged in patients with decompensated liver disease and advanced liver dysfunction, as recommended by the EASL-EORTC guidelines, due to the high risk of precipitating acute-on-chronic liver failure 1, 2
The EASL-EORTC guidelines specifically state that TACE should not be performed in patients with decompensated cirrhosis, highlighting the importance of avoiding interventions that may worsen liver function 1

Hepatic artery embolization should be avoided in patients with liver involvement by vascular malformations, as it is a palliative measure associated with significant morbidity, according to the American Association for the Study of Liver Diseases 3, 4
Embolization procedures can precipitate systemic inflammatory responses leading to multiorgan failure, severe coagulopathy, and disseminated intravascular coagulation, emphasizing the need for caution in patients with liver disease 1
In patients with portosystemic shunting, embolization is specifically contraindicated as it can worsen the hyperdynamic circulatory state, as noted by the American Association for the Study of Liver Diseases 3, 4

For patients with decompensated liver disease, immediate transplant evaluation is indicated, as recommended by the American Association for the Study of Liver Diseases, with 1-year survival rates of 78% compared to <10% without transplant 5
Early referral to a transplant center is critical, as delayed evaluation can worsen mortality, highlighting the importance of prompt action in managing decompensated liver disease 5

Identifying and treating precipitating factors, including infection, gastrointestinal bleeding, and hepatotoxic exposures, is crucial in managing decompensated liver disease, as recommended by the American Association for the Study of Liver Diseases 5
Empirical broad-spectrum antibiotics are mandatory if infection is suspected, and organ support with terlipressin plus albumin for hepatorenal syndrome, and vasopressors for hemodynamic instability, may be necessary, as noted by the American Association for the Study of Liver Diseases 5

Never delaying transplant evaluation in decompensated patients is critical, as this is the most critical error that worsens mortality, emphasizing the importance of prompt action in managing decompensated liver disease 5
Avoiding any procedure that could precipitate acute-on-chronic liver failure is essential, as post-discharge prognosis without transplant is dismal with 1-year survival <25%, highlighting the need for caution in managing decompensated liver disease 5